Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Sarepta Therapeutics Inc. (NASDAQ:SRPT)with a price target of $22.
Roth Capital analyst Debjit Chattopadhyay maintained Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) with a $22 price target, as the company initiated dosing in a clinical study of …
In a research report released today, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on NeoGenomics Inc. (NASDAQ:NEO) with a $7 price target, …
In a research report sent to investors today, Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating on Nektar Therapeutics (NASDAQ:NKTR) with a …
Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) with a price target of $22, which represents a potential …
In a research report released Thursday, Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating on bluebird bio Inc (NASDAQ:BLUE) with a price …
Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating on NeoGenomics Inc. (NASDAQ:NEO) with a price target of $7.
Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) with a $22 price target, which represents a potential upside of …
Roth Capital analyst Debjit Chattopadhyay initiated coverage on Hyperion Therapeutics (NASDAQ:HPTX) with a Buy rating and a $34 price target, which represents a potential upside of 38% …
Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating on Prosensa Holding (NASDAQ:RNA) with a price target of $17, which represents a potential …
